Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
In this study, the safety, tolerability and efficacy of DLX105 administered topically onto
the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.